2,830
Views
14
CrossRef citations to date
0
Altmetric
Plenary Paper

MicroRNA-126 is a regulator of platelet-supported thrombin generation

, ORCID Icon, , ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 746-755 | Received 25 May 2020, Accepted 25 May 2020, Published online: 12 Jun 2020

References

  • Versteeg HH, Heemskerk JW, Levi M, Reitsma PH New fundamentals in hemostasis. Physiol Rev 2013;93:327–358. DOI:10.1152/physrev.00016.2011.
  • Sunderland N, Skroblin P, Barwari T, Huntley RP, Lu R, Joshi A, Lovering RC, Mayr M. MicroRNA biomarkers and platelet reactivity: the Clot Thickens. Circ Res 2017;120:418–435. DOI:10.1161/CIRCRESAHA.116.309303.
  • Bartel DP MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215–233. DOI:10.1016/j.cell.2009.01.002.
  • Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961–966. DOI:10.1038/nsmb.1651nsmb.1651[pii].
  • Jakob P, Kacprowski T, Briand-Schumacher S, Heg D, Klingenberg R, Stahli BE, Jaguszewski M, Rodondi N, Nanchen D, Raber L, et al. Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. Eur Heart J 2017;38:511–515. DOI:10.1093/eurheartj/ehw563.
  • Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290–299. DOI:10.1016/j.jacc.2012.03.056.
  • Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley SR, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013;112:595–600. CIRCRESAHA.111.300539 [pii]. DOI:10.1161/CIRCRESAHA.111.300539
  • Hanumanthaiah R, Day K, Jagadeeswaran P Comprehensive analysis of blood coagulation pathways in teleostei: evolution of coagulation factor genes and identification of zebrafish factor VIIi. Blood Cells Mol Dis 2002;29:57–68. DOI:S1079979602905346
  • Jagadeeswaran P, Sheehan JP, Craig FE, Troyer D Identification and characterization of zebrafish thrombocytes. Br J Haematol 1999;107:731–738. bjh1763 [pii]. doi:10.1046/j.1365-2141.1999.01763.x
  • Niwa R, Slack FJ The evolution of animal microRNA function. Curr Opin Genet Dev 2007;17:145–150. S0959-437X(07)00029-9 [pii] doi:10.1016/j.gde.2007.02.004.
  • O’Connor MN, Salles II, Cvejic A, Watkins NA, Walker A, Garner SF, Jones CI, Macaulay IC, Steward M, Zwaginga JJ, et al. Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood 2009;113:4754–4762. blood-2008-06-162693 [pii]. DOI:10.1182/blood-2008-06-162693
  • Lin HF, Traver D, Zhu H, Dooley K, Paw BH, Zon LI, Handin RI Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood 2005;106:3803–3810. DOI:10.1182/blood-2005-01-0179.
  • Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton AC, Armstrong PC, et al. Association of microRNAs and YRNAs with platelet function. Circ Res 2016;118:420–432. DOI:10.1161/CIRCRESAHA.114.305663.
  • Zou J, Li WQ, Li Q, Li XQ, Zhang JT, Liu GQ, Chen J, Qiu XX, Tian FJ, Wang ZZ, et al. Two functional microRNA-126s repress a novel target gene p21-activated kinase 1 to regulate vascular integrity in zebrafish. Circ Res 2011;108:201–209. DOI:10.1161/CIRCRESAHA.110.225045.
  • Kontarakis Z, Rossi A, Ramas S, Dellinger MT, Stainier DYR Mir-126 is a conserved modulator of lymphatic development. Dev Biol 2018;437:120–130. DOI:10.1016/j.ydbio.2018.03.006.
  • Grabher C, Payne EM, Johnston AB, Bolli N, Lechman E, Dick JE, Kanki JP, Look AT Zebrafish microRNA-126 determines hematopoietic cell fate through c-Myb. Leukemia 2011;25:506–514. DOI:10.1038/leu.2010.280.
  • Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS, Parant JM, Yost HJ, Kanki JP, Chien CB The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn 2007;236:3088–3099. DOI:10.1002/dvdy.21343.
  • Ablain J, Durand EM, Yang S, Zhou Y, Zon LI A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. Dev Cell 2015; 32(6)756–764 S1534-5807(15)00075-1 [pii] doi:10.1016/j.devcel.2015.01.032..
  • Blin A, Le Goff A, Magniez A, Poirault-Chassac S, Teste B, Sicot G, Nguyen KA, Hamdi FS, Reyssat M, Baruch D Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics. Sci Rep 2016;6:21700. DOI:10.1038/srep21700.
  • Strassel C, Brouard N, Mallo L, Receveur N, Mangin P, Eckly A, Bieche I, Tarte K, Gachet C, Lanza F Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. Blood 2016;127:2231–2240. DOI:10.1182/blood-2015-09-670208.
  • Pineault N, Robert A, Cortin V, Boyer L Ex vivo differentiation of cord blood stem cells into megakaryocytes and platelets. Methods Mol Biol 2013;946:205–224. DOI:10.1007/978-1-62703-128-8_13.
  • Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995;85:402–413. doi:10.1182/blood.V85.2.402.402
  • Panuganti S, Schlinker AC, Lindholm PF, Papoutsakis ET, Miller WM Three-stage ex vivo expansion of high-ploidy megakaryocytic cells: toward large-scale platelet production. Tissue Eng Part A 2013;19:998–1014. DOI:10.1089/ten.TEA.2011.0111. 7–8
  • Garcia A, Dunoyer-Geindre S, Zapilko V, Nolli S, Reny JL, Fontana P Functional Validation of microRNA-126-3p as a platelet reactivity regulator using human haematopoietic stem cells. Thromb Haemost 2019;119:254–263. DOI:10.1055/s-0038-1676802.
  • Alberio L, Ravanat C, Hechler B, Mangin PH, Lanza F, Gachet C Delayed-onset of procoagulant signalling revealed by kinetic analysis of COAT platelet formation. Thromb Haemost 2017;117:1101–1114. DOI:10.1160/TH16-09-0711.
  • Colucci G, Stutz M, Rochat S, Conte T, Pavicic M, Reusser M, Giabbani E, Huynh A, Thurlemann C, Keller P, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood 2014;123:1905–1916. DOI:10.1182/blood-2013-04-497123.
  • Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the antiplatelet drug resistances and ischemic events study. Circulation 2012;125:3201–3210. CIRCULATIONAHA.111.085464 [pii]. doi:10.1161/CIRCULATIONAHA.111.085464.
  • Pordzik J, Pisarz K, De Rosa S, Jones AD, Eyileten C, Indolfi C, Malek L, Postula M The potential role of platelet-related microRNAs in the development of cardiovascular events in high-risk populations, including diabetic patients: a review. Front Endocrinol (Lausanne) 2018;9:74. DOI:10.3389/fendo.2018.00074.
  • Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 2016;17:204–212. DOI:10.1093/bib/bbv056.
  • Kok MG, Halliani A, Moerland PD, Meijers JC, Creemers EE, Pinto-Sietsma SJ Normalization panels for the reliable quantification of circulating microRNAs by RT-qPCR. FASEB J 2015;29:3853–3862. DOI:10.1096/fj.15-271312.
  • Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.. doi: 10.1186/gb-2002-3-7-research0034
  • Giacomotto J, Rinkwitz S, Becker TS Effective heritable gene knockdown in zebrafish using synthetic microRNAs. Nat Commun 2015;6:7378. DOI:10.1038/ncomms8378.
  • Fontana P, Berdague P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, De Moerloose P, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 2010;8:2614–2623. DOI:10.1111/j.1538-7836.2010.04063.x.
  • Fish RJ, Di Sanza C, Neerman-Arbez M Targeted mutation of zebrafish fga models human congenital afibrinogenemia. Blood 2014;123:2278–2281. blood-2013-12-547182 [pii]. DOI:10.1182/blood-2013-12-547182.
  • Hu Z, Liu Y, Huarng MC, Menegatti M, Reyon D, Rost MS, Norris ZG, Richter CE, Stapleton AN, Chi NC, et al. Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway. Blood 2017;130:666–676. DOI:10.1182/blood-2017-02-765206.
  • Liu Y, Kretz CA, Maeder ML, Richter CE, Tsao P, Vo AH, Huarng MC, Rode T, Hu Z, Mehra R, et al. Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. Blood 2014;124:142–150. DOI:10.1182/blood-2014-03-561027.
  • Koh CY, Kumar S, Kazimirova M, Nuttall PA, Radhakrishnan UP, Kim S, Jagadeeswaran P, Imamura T, Mizuguchi J, Iwanaga S, et al. Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. PLoS One 2011;6:e26367. DOI:10.1371/journal.pone.0026367.
  • Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000;95:1694–1702. doi:10.1182/blood.V95.5.1694.005k24_1694_1702
  • Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415(6868):175–179. DOI:10.1038/415175a.
  • Pasalic L, Wing-Lun E, Lau JK, Campbell H, Pennings GJ, Lau E, Connor D, Liang HP, Muller D, Kritharides L, et al. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J Thromb Haemost 2018;16:1198–1210. DOI:10.1111/jth.14008.
  • Didelot M, Docq C, Wahl D, Lacolley P, Regnault V, Lagrange J Platelet aggregation impacts thrombin generation assessed by calibrated automated thrombography. Platelets 2018;29:156–161. DOI:10.1080/09537104.2017.1356452.
  • Bao Y, Wang S, Gao Y, Zhang W, Jin H, Yang Y, Li J MicroRNA-126 accelerates IgE-mediated mast cell degranulation associated with the PI3K/Akt signaling pathway by promoting Ca(2+) influx. Exp Ther Med 2018;16:2763–2769. DOI:10.3892/etm.2018.6510.
  • Wannemacher KM, Wang L, Zhu L, Brass LF The role of semaphorins and their receptors in platelets: lessons learned from neuronal and immune synapses. Platelets 2011;22:461–465. DOI:10.3109/09537104.2011.561891.
  • Heemskerk JW, Mattheij NJ, Cosemans JM Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013;11:2–16. DOI:10.1111/jth.12045.
  • Melki I, Tessandier N, Zufferey A, Boilard E Platelet microvesicles in health and disease. Platelets 2017;28:214–221. DOI:10.1080/09537104.2016.1265924.
  • Kalambokis GN, Oikonomou A, Baltayiannis G, Christou L, Kolaitis NI, Tsianos EV Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis. Hepatol Res 2016;46:E36–44. DOI:10.1111/hepr.12520.
  • Silvain J, O’Connor SA, Yan Y, Kerneis M, Hauguel-Moreau M, Zeitouni M, Overtchouk P, Ankri A, Brugier D, Vicaut E, et al. Biomarkers of thrombosis in ST-segment elevation myocardial infarction: a substudy of the ATOLL trial comparing enoxaparin versus unfractionated heparin. Am J Cardiovasc Drugs 2018. DOI:10.1007/s40256-018-0294-z. 18 6 503–511
  • Basak I, Bhatlekar S, Manne BK, Stoller M, Hugo S, Kong X, Ma L, Rondina MT, Weyrich AS, Edelstein LC, et al. miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway. J Thromb Haemost 2019. DOI:10.1111/jth.14382. 17 3 511–524
  • Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–1330. DOI:10.1056/NEJMoa1709118. 14